Cardio/Pulmonary

JAMA Patient Education Page on what is Interstitial Lung Disease https://t.co/BDbV6I53NH https://t.co/1OtTiJHkdt

Links:

Dr. John Cush @RheumNow( View Tweet )
Puzzle pieces

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic

Read Article
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs. @RheumNow #EULAR2025 #OP0033 https://t.co/nEiTWQEqsP
Dr. John Cush @RheumNow( View Tweet )
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/HC0skwUKQG
Dr. John Cush @RheumNow( View Tweet )
FDA adds new warning for "myocarditis" to the Pfizer and Moderna COVID-19 vaccines (prev mainly assoc w/ Moderna) - risk is 8 per 1 million people for those on 2023-2024 COVID shots, most common in males ages 12 to 24. Generally good outcomes seen. https://t.co/QZbTRaKGH1 https://t.co/1cAUw73eqF

Links:

Dr. John Cush @RheumNow( View Tweet )
Jekyll and Hyde: which RA-ILD is it? Dr. David Liew reports on abstract OP0329 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/oH9nXaKRDz https://t.co/iUAJk2Q856

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

PCR: Prevalence, Cost, & Risk (6.27.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article
Prospective KORAIL study of 138 RA pts w/ ILD on chest CT -60% had UIP ILD. After F/U of 2.9 yrs, 35% had RA-ILD progression. Baseline predictors of progression = UIP, ILD >10 %, DLCO %pred, CCP+, KL-6 levels, RA Dz activity. Useful to ID high-risk RA-ILD pts.

Dr. John Cush @RheumNow( View Tweet )

Aortic aneurysms w/ GCA. TriNetX study of 7,294 Bx-proven GCA vs 265,948 controls w/ tension HA. GCA had signif higher 5-yr risk of aortic aneurysms (3.59%; aHR 1.98), including thoracic thoracoabdominal & abdominal. Carotid A stenosis also incr in GCA (aHR 1.59) https://t.co/15fwlHa0FG
Dr. John Cush @RheumNow( View Tweet )
What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. https://t.co/tgfsU3uFVo
Dr. John Cush @RheumNow( View Tweet )
What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the https://t.co/JgmfxGa6TY
Dr. John Cush @RheumNow( View Tweet )
A new mechanism of action in SARD-ILD Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x
Dr. John Cush @RheumNow( View Tweet )
EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush @RheumNow( View Tweet )
New ideas in gout management Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX

Links:

Dr. John Cush @RheumNow( View Tweet )
heart in a puzzle

What would it take for JAKs to ROCK the boat?

David Liew, FRACP

JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might

Read Article
Lung,AI,Pleura

A new mechanism of action in SARD-ILD

Aurelie Najm, MD, PhD

Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was 

Read Article
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 https://t.co/jPAai9FLkb
Dr. John Cush @RheumNow( View Tweet )
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/M6uU6i5cW4
Dr. John Cush @RheumNow( View Tweet )
Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD). https://t.co/2zuxF1PY3Q. https://t.co/Icck4qE76X

Links:

Dr. John Cush @RheumNow( View Tweet )
#CAR-T in active #scleroderma #diffuse open label @sclerodermaUM presented improvement in #nailfold #capillary patterns Suggesting #vascular recovery Hope is for lungs, skin and survival to improve but These are ▶️ Early days ?risk OP0338 #EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk

Links:

Janet Pope @Janetbirdope( View Tweet )
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA? 🔹️245 pts 🔹️CRP recorded for past 5y 🔹️sustained high CRP in 40% 🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis POS0714 #EULAR2025 @RheumNow https://t.co/jAlj3sr95H

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Manifestations of relapsing polychondritis @Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Recent Blogs

Overlap Syndrome with ILD

Jack Cush, MD
Cush RheumThought ILD

How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?

Read Post

Best of 2023: New ACR RA-ILD Treatment Guidelines – What Were They Smoking!?

Richard Conway, MBBChBAO, PhD
Lungs ILD
Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. There is a very limited evidence base supporting treatment and therefore the recent release of ACR guidelines is to be welcomed. However, the published guidelines appear discordant with the best available evidence base.  Read Post
×